Dr. Emily Stein is Interim Chief of the Endocrine Service, Director of Research of the Metabolic Bone Service and an Endocrinologist at HSS. She is also an Associate Professor of Medicine at Weill Cornell Medical College. Dr. Stein received her undergraduate degree from Yale University, where she was elected to Phi Beta Kappa and graduated Magna Cum Laude. She received her medical degree from the Albert Einstein College of Medicine where she received a Rudin Fellowship for academic excellence and was elected to Alpha Omega Alpha. She completed her internship and residency at Columbia Presbyterian Medical Center. She was a fellow in Endocrinology and Metabolism at the combined program at New York Hospital/Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center. She also completed a Masters Degree in Clinical Investigation at the Cornell Graduate School.
Dr. Stein is a member of the American Society of Bone and Mineral Research, and received both a Young investigator Award and Junior Faculty Osteoporosis Research Award from this society. Her research, supported by the National Institutes of Health, American Society of Bone and Mineral Research, as well as private foundations has focused on investigating the quality of bone in patients with osteoporotic fractures, the skeletal effects of glucocorticoids, chronic kidney disease, organ transplant and bariatric surgery. She has also studied abnormalities of vitamin D metabolism in different populations. Her recent work focuses on how bone quality impacts outcomes after orthopedic surgery. Dr. Stein is leading a randomized placebo controlled clinical trial studying whether abaloparatide treatment improves outcomes after spinal fusion surgery.
Dr. Stein’s clinical practice is focused on patients with osteoporosis and metabolic bone disease. Dr. Stein has also played a role in shaping evidence based clinical practice decisions in the field, serving as a member of the American Society of Bone and Mineral Research Professional Practice Committee, the International Society of Clinical Densitometry Scientific Advisory Council and the American College of Rheumatology Glucocorticoid Induced Osteoporosis Quality Measure Development Panel.
Internal Medicine, Endocrinology, Metabolic Bone
Osteoporosis and Metabolic Bone Health
Osteoporosis, Metabolic Bone Disorders, Calcium and Phosphate Disorders
If your insurance is not listed, please call our office if you have questions regarding your insurance coverage. If you have out-of-network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.
Interim Chief, Endocrine Service, Hospital for Special Surgery
Co-Director of the Bone Health and Implant Integration Program, HSS Research Institute
Director of Research, Division of Endocrinology and Metabolic Bone, Hospital for Special Surgery
Attending Physician, Hospital for Special Surgery
Associate Research Scientist, Hospital for Special Surgery
Associate Professor of Medicine, Weill Cornell Medical College
American Society for Bone and Mineral Research, Ethics Committee (term 2020-2023)
American Society for Bone and Mineral Research, Development Committee (term 2015-2018)
American Society for Bone and Mineral Research, Professional Practice Committee (term 2012-2015)
American Society for Bone and Mineral Research, Member 2005-present
International Society for Clinical Densitometry, Scientific Advisory Council
International Society for Clinical Densitometry, Member 2011-present
American College of Rheumatology – Glucocorticoid Induced Osteoporosis Quality Measure Development Panel, member, 2011
Endocrine Society, Member 2005-present
08/2004 American Board of Internal Medicine
10/2006 American Board of Internal Medicine, Endocrinology and Metabolism
Marina Kellen French Scholar, 2019
Fellow of the American Society of Bone and Mineral Research, 2018
American Society for Bone and Mineral Research Young Investigator Travel Award, 2012
Junior Faculty Osteoporosis Research Award, American Society for Bone and Mineral Research, 2011
American Society for Bone and Mineral Research Young Investigator Travel Award, 2011
American Society for Bone and Mineral Research Young Investigator Award, 2010
Endocrine Society Travel Award, 2009
Clinical Research Feasibility Funds (CreFF) Award, Awarded by the Weill Cornell CTSA, 2005
Alpha Omega Alpha 2001 Rudin Distinguished Scholar, 1997-2001
American Medical Women's Association Janet M. Glasgow Achievement Citation, 2001
College Council Award Yale University, 1997
Albert Einstein College of Medicine, New York
Yale University, Connecticut
Internship: Internal Medicine, New York Presbyterian Hospital - Columbia
Residency: Internal Medicine, New York Presbyterian Hospital - Columbia
Fellowship: Endocrinology and Metabolism, Weill Cornell Medical College/ Memorial Sloan Kettering Cancer Center
English
Deputy Editor, Journal of Bone and Mineral Research
For all publications, please see the PubMed listing.
Stein, E., Shane, E. Secondary osteoporosis. In: Bilezikian, J. editor Endocrinology and Metabolism Clinics of North America. Philadelphia: W.B. Saunders Company; 2003. 114-134.
Stein, E., Shane, E. Bone loss in patients before and after lung transplantation. In: Compston, J. and Shane, E. editors. Bone Disease of Organ Transplantation. Amsterdam: Elsevier Academic Press; 2005. 303-318.
Stein, E., Ebeling, P., Shane E. Post-transplant Osteoporosis. In: Breen, T. editor. Endocrinology and Metabolism Clinics of North America. 2007. 36(4): 937-63.
Stein, E, Shane, E. Transplantation Osteoporosis. In: Adler, R. editor. Osteoporosis, Pathophysiology and Clinical Management. New York: Humana Press; 2010. 569-620.
Stein, EM, Compston, J, Shane, E. Transplantation Osteoporosis. In: Bilezikian, JP. Editor. Osteoporosis in Men. London: Elsevier; 2010. 443-452.
Yin M, Stein E. The effect of antiretrovirals on vitamin D. Clin Infect Dis. 2011 Feb 1;52(3):406-8.
Stein EM, Shane E. Vitamin D in organ transplantation. Osteoporos Int. 2011 Jul;22(7):2107-18. Epub 2011 Jan 5. Epub 2011 Jan 5.
Stein EM, Shane E. Osteoporosis in Organ Transplant Patients. In: Marcus R, Feldman D, Dempster D, Luckey M, Cauley J Editors. Osteoporosis 4th Edition. San Diego: Elsevier: 2013. 1349-1374.
Stein EM and Silverberg SJ. Bone loss after bariatric surgery: causes, consequences and management. Lancet Diabetes Endocrinol 2014; 2: 165-174.doi:10.1016/S0140-6736(08)61345-8.
Sutter SA and Stein EM. The Skeletal Effects of Inhaled Glucocorticoids. Curr Osteoporos Rep. 2016 Jun;14(3):106-13. doi: 10.1007/s11914-016-0308-1.
Dr. Stein is a clinical researcher in the field of metabolic bone disease. She has extensive research experience in the areas of postmenopausal osteoporosis, glucocorticoid induced osteoporosis, vitamin D metabolism, and the use of non-invasive techniques to evaluate bone structure and strength, aspects of bone quality.
Dr. Stein has been Principal Investigator (PI) or Co-investigator of studies investigating the pathophysiology and treatment of postmenopausal and secondary osteoporosis. Her research has involved several multi-disciplinary collaborations, with orthopedists, rheumatologists, nephrologists, and engineers. She received a K23 award from the NIH to evaluate the effects of parathyroid hormone and chronic kidney disease on skeletal microarchitecture and strength in postmenopausal women. This work has led to the identification of several novel microstructural mechanisms for fragility fractures. Recent work has focused on addressing the mechanisms by which various disease states and medications negatively impact bone quality. She was the recipient of a Junior Faculty Osteoporosis Research Award from the ASBMR to investigate the effects of oral glucocorticoids on skeletal structure and strength and is currently Principal Investigator of a study investigating the skeletal impact of epidural glucocorticoids.
Dr. Stein has also served as PI or Co-investigator for randomized clinical trials aimed at improving skeletal outcomes with different pharmacologic and behavioral interventions, including teriparatide treatment for premenopausal women with idiopathic osteoporosis, bisphosphonate treatment for prevention of bone loss after solid organ transplantation, treatment of vitamin D deficiency in obese individuals prior to bariatric surgery, and potassium citrate treatment for prevention of postmenopausal bone loss. She has served as a member of the Data Safety Monitoring Board for two randomized clinical trials.
Other research interests include investigation of bone quality deficits in other disease states as well as the relationship between pre-operative bone quality and outcomes after orthopedic procedures, and the creation of clinical trials investigating whether different pharmacologic therapies can improve these outcomes.
HSS has a long history of supporting appropriate relationships with industry because they advance HSS's mission to provide the highest quality patient care, improve patient mobility, and enhance the quality of life for all, and to advance the science of orthopedic surgery, rheumatology, and their related disciplines through research and education.
Below are the healthcare industry relationships reported by Dr. Stein as of March 27, 2023.
HSS and its physicians make this information available to patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest and Commitment Policy prohibits physicians from collecting royalties on products they develop that are used on patients at HSS.
Patients should feel free to ask their HSS physicians questions about these relationships.
